Protagonist Therapeutics

Unpartnered assets: on the shelf or hidden treasure?
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
Flag link:
Biopharma stocks go back to bleak
Biopharma stocks go back to bleak
EP Vantage
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Flag link:
Biotechs put assets up for sale and on the shelf in quarterly pipeline clear-outs
Biotechs put assets up for sale and on the shelf in quarterly pipeline clear-outs
Fierce Biotech
Xilio Therapeutics
Protagonist Therapeutics
Arbutus BioPharma
Aptinyx
Flag link:
Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitis
Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitis
Fierce Biotech
Protagonist Therapeutics
clinical trials
ulcerative colitis
Entyvio
Flag link:
Protagonist seeks an Ideal readout
Protagonist seeks an Ideal readout
EP Vantage
Protagonist Therapeutics
PN-943
clinical trials
ulcerative colitis
Flag link:
Protagonist posts phase 2 hormone replacement data, pitching for lead role in genetic iron overload disease
Protagonist posts phase 2 hormone replacement data, pitching for lead role in genetic iron overload disease
Fierce Biotech
Protagonist Therapeutics
clinical trials
Flag link:
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
Yahoo Finance
Protagonist Therapeutics
clinical trials
FDA
rusfertide
polycythemia
Flag link:
FDA hits pause on Protagonist's blood cancer med after mouse study turns up skin tumors
FDA hits pause on Protagonist's blood cancer med after mouse study turns up skin tumors
Fierce Biotech
Protagonist Therapeutics
clinical trials
blood cancer
FDA
Flag link:
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Fierce Biotech
JNJ
Protagonist Therapeutics
M&A
Crohn's Disease
PTG-200
Flag link:
5 Biotech IPOs Lead The Way In 2016
5 Biotech IPOs Lead The Way In 2016
Seeking Alpha
biotech
IPOs
AveXis
Clearside Biomedical
Protagonist Therapeutics
Reata Pharmaceuticals
Bluebird Bio
Flag link:
Protagonist Therapeutics, Ironwood sign peptide drug deal
Protagonist Therapeutics, Ironwood sign peptide drug deal
Bizjournals.com
peptides
Protagonist Therapeutics
Ironwood
Flag link: